Harnessing cGAS-STING Pathway for Cancer Immunotherapy: From Bench to Clinic

Dae Yong Lee, Kristin Huntoon, Minjeong Kang, Yifei Lu, Thomas Gallup, Wen Jiang, Betty Y.S. Kim

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Recent advances in cancer immunotherapy have accomplished clinical successes in certain cancer models over the past decade. However, cancer treatments with adoptive cell transfer or immune checkpoint blockade (ICB) have shown critical limitations against solid tumors, which comprise the majority of human cancers. Thus, novel cancer immunotherapy which harnesses innate immunity process may be required in these tumor types. Cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, one of the innate immune sensors, has gained interest in the field of immuno-oncology as activation of this pathway can drive both innate and adaptive immune responses among immunosuppressive tumor microenvironments. Recently, various cGAS-STING-activating strategies have been intensively investigated to achieve durable and widespread therapeutic responses in in vivo models. These meaningful preclinical outcomes have enabled several clinical trials. This review discusses agents targeting various aspects of the cGAS-STING pathway in cancer immunotherapy from benchtop to bedside. Moreover, various approaches to improve the clinical feasibility of cGAS-STING-activating strategies are delineated.

Original languageEnglish (US)
Article number2200040
JournalAdvanced Therapeutics
Issue number10
StatePublished - Oct 2022
Externally publishedYes


  • bioengineering
  • cancer immunotherapy
  • cyclic GMP-AMP synthase-stimulator of interferon genes pathway
  • microtechnology
  • nanotechnology
  • stimulator of interferon genes agonist

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Pharmaceutical Science
  • Genetics(clinical)
  • Biochemistry, medical
  • Pharmacology (medical)


Dive into the research topics of 'Harnessing cGAS-STING Pathway for Cancer Immunotherapy: From Bench to Clinic'. Together they form a unique fingerprint.

Cite this